0
Is olaparib the only PARP inhibitor that has been approved?
- 1 people answered
0 Vote
1 Contributor
1558 Views 
0 Saved
0 Vote 1 Contributor1558 Views 0 SavedYou might also be interested in
Breast cancer can be diagnosed at different stages and can grow at different rates. This means people can have different treatments, depending on what will work best for them. To determine if your symptoms are caused by breast cancer or a benign breast condition, your doctor will do a thorough ph....
Well! That’s a very vague statement. How can you be so certain that there are no oncologists on community? If you ask a valid question, you would get some trusted advises from the specialist doctors using CrediCommunity and from those advises you can decide what to digest. It can be hard to know wh....
Rahul Sharma
Yes, PARP inhibitors are relatively newer class of drugs and scientists have just begun to explore their functionality and usage in Cancer treatment. LYNPARZA is the first and only PARP inhibitor approved in 2 distinct settings: For the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy. For the treatment of adult patients with suspected deleterious germline BRCA-mutated advanced ovarian cancer which has been treated with 3 or more prior lines of chemotherapy. Patients should be selected for therapy based on an FDA-approved companion diagnostic for LYNPARZA. Poly (ADP-ribose) Polymerase, or PARP, enzymes mediate DNA repair by transferring ADP-ribose units to preexisting ADP-ribose chains on proteins and to proteins. This ADP–ribosylation process recruits DNA repair enzymes, thereby maintaining genomic integrity. Inhibiting this process can lead to the accumulation of DNA damage and, ultimately, cell death.